Skip to content

308nm excimer laser vs tacrolimus Secretary ointment for the treatment of the stationary phase surface neck vitiligo: the efficacy and safety of multi-center, randomized, open, parallel, self-controlled clinical trials.

308nm excimer laser vs tacrolimus Secretary ointment for the treatment of the stationary phase surface neck vitiligo: the efficacy and safety of multi-center, randomized, open, parallel, self-controlled clinical trials.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002595
Enrollment
Unknown
Registered
2014-09-21
Start date
2012-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo

Interventions

test group:308nm excimer laser
control group:tacrolimus ointment

Sponsors

The First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) age 14-65 years old, inpatient or outpatient, male or female; (2) meet the diagnostic criteria of clinically diagnosed primary quiescent face and neck vitiligo patients; (3) subjects volunteered to participate, be required to sign an informed consent form; (4) leukoplakia spread in the neck of the double-side, with at least one lesions greater than 1cm in diameter;

Exclusion criteria

Exclusion criteria: (1) pregnant and lactating women; (2) serious heart, liver, renal insufficiency; (3) pre-cancerous skin lesions; (4) systemic lupus erythematosus (SLE), dermatomyositis ultraviolet treatment contraindications; (5) with immunosuppressive therapy; Nearly 2 months (6) received corticosteroids, calcineurin inhibitors, NB-UVB excimer laser treatment, any treatment received nearly January, at the same time to participate in clinical trials; (7) tacrolimus sensitive.; (8) secondary vitiligo (such as secondary to discoid lupus erythematosus, chronic eczema, vitiligo); (9) can not adhere to treatment.

Countries

China

Contacts

Public ContactXing-hua Gao
gaobarry@hotmail.com+86 13940152467

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026